Advance your therapies to clinical trials with the genO-hPD1 mouse model

The genO-hPD-1 mouse model helped Anaveon reach clinical trials

Our genO-hPD-1 mouse model was used by Anaveon to test the efficacy and MOA of their PD-1 targeted IL-2Rβγ agonist, ANV600.

‍

Mechanism of action analysis of ANV600 using genO-hPD-1 mice

‍

‍

Efficacy assessment of ANV600 using genO-hPD-1 mice

‍

This publication shows that genO-hPD-1 mice can help develop new strategies to further improve ICI treatments.​

‍

Key features of the genO-hPD-1 mouse:

• Physiological regulation and expression of a humanized PD-1
• Lack of expression of the murine target gene
• Fully functional mouse immune system
• Available on different genetic backgrounds C57BL/6 & BALB/c

‍

The impact of our models on our partners' research

Here is a non exhaustive list of scientific articles that were published using our genO-hDP-1 model:

• ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy, Murer et al., J Immunother Cancer, 2025

• CCX559 is a potent orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity, Sullivan et al., PLoS One, 2023

• Human PD-1 agonist treatment alleviates neutrophilic asthma by reprogramming T cells, Helou et al., J Allergy Clin Immunol, 2022

• ‍An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy, Chan et al., Nat Cancer, 2022

• Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1 + Activated T Cells, Dovedi et al., Cancer Discov, 2020